医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Japan-India collaboration yields a novel treatment method for male urethral stricture

2018年11月25日 PM08:30
このエントリーをはてなブックマークに追加


 

TOKYO

A novel and relatively pain-less treatment method for male urethral stricture using patients own buccal mucosal cells has been reported as successful in four out of six patients. The study has been published in International Journal of Urology (https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852) which is the official journal of Japanese Urological Association, is a result of collaboration between Japanese biomaterial technology and an Indian urologist Dr Suryaprakash Vaddi.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181125005123/en/

BEES-HAUS, an illustrative overview of the steps from tissue harvest to cell transplant for urethral ...

BEES-HAUS, an illustrative overview of the steps from tissue harvest to cell transplant for urethral stricture and a glimpse of the results (Graphic: Business Wire)

Majority of male urethral strictures reported in the developed world are due to iatrogenic causes (BPH surgery, prostate cancer treatment). In the developing countries, the major causes are inflammation and trauma. In 30% patients, the cause is unknown. The conventional treatment involves either endoscopic intervention or open surgery. In surgical treatment, under general anesthesia, patient’s Buccal mucosa is harvested and used as a patch to enlarge the narrowed urethra. In both methods, restenosis occurs in up to 40% of patients. In our method called as BEES-HAUS (Buccal epithelium Expanded and Encapsulated in Scaffold – Hybrid Approach for Urethral Stricture), we harvested a small piece of the buccal tissue and after culturing the cells in the lab without animal protein, embedded in scaffold and transplanted through endoscopy. Both harvesting and transplant doesn’t require general anesthesia, making the procedure relatively easier to the clinician and less painful to the patient. Going by the data, this procedure has a potential to help approximately 30,000 patients every year in Japan. In the U.S, total annual expenditure due to stricture is about 200 Million US Dollars, said Dr Vaddi, the lead author of the paper.

GN Corporation, which has coordinated the interaction between Japanese biomaterial scientists and clinicians in India through NCRM (Nichi-In Centre for Regenerative Medicine), has applied for a patent for this invention and has signed a MoU for collaboration with JBM Inc (www.jbmed.net), Tokyo, Japan, for exploring opportunities to make this an approved clinical solution in the future following the regulatory protocols as per Japanese ministry of health.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181125005123/en/

CONTACT

Samuel JK Abraham
info@gncorporation.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作